Knight CNS
Sector: Manufacturing (Industrial) • Location: Latin America and the Caribbean Region
Source: International Finance Corporation (IFC)
IFC is considering providing an up to US$40 million loan to Knight Therapeutics Inc. (“Knight” or the “Company”), a pan-American (ex-USA) specialty pharmaceutical company headquartered in Canada with significant operations in Latin America, to partially finance the acquisition of the rights to manufacture, market and sell Exelon® (rivastigmine) in Canada and Latin America (the “Territory”), as wel
- Status
- Prospective
- Sector
- Manufacturing (Industrial), Government, Commercial
- Location
- Brazil
- Updated
- 19 Nov 2026
- Source
- International Finance Corporation (IFC)
ConstructChat
Ask ConstructChat about Knight CNS
Pick a question to edit it, or write your own.
First answer free · no account
Project Information FAQ
Project Information
Participants
Sponsoring Agency |
Status
Original status | active |
Taiyo status | Prospective |
Taiyo last update | 2026-11-19 |
Contact
| Not available for this record. |
Description
Description | IFC is considering providing an up to US$40 million loan to Knight Therapeutics Inc. (“Knight” or the “Company”), a pan-American (ex-USA) specialty pharmaceutical company headquartered in Canada with significant operations in Latin America, to partially finance the acquisition of the rights to manufacture, market and sell Exelon® (rivastigmine) in Canada and Latin America (the “Territory”), as well as an exclusive license to use the intellectual property and the Exelon® trademark, from Novartis within the Territory (the “Exelon Acquisition”). Exelon® is indicated for the symptomatic treatment of mild to moderately severe dementia in people with Alzheimer’s disease and Parkinson’s disease.Founded in 2014 in Montreal, Canada, Knight is pan-American (ex-USA) specialty pharmaceutical company that focused on acquiring or in-licensing and commercializing pharmaceutical products in Canada and Latin America.In 2019, Knight acquired a controlling stake in Grupo Biotoscana (“GBT”), a specialty pharmaceutical company with a presence across Latin America. In August 2020, Knight completed the 100% acquisition of GBT. With the GBT acquisition, Knight has expanded its operations in Latin America through a direct presence in 10 countries. |
Original sector | other |
Budget |
Location
Country | Brazil |
Source
Source | International Finance Corporation (IFC) |
URL |
More Details
Record type | Project |
Sector | Manufacturing (Industrial), Government, Commercial |
Article published date | 2025-08-08 |
Research
Free account
View all details
You are reading the public part. A free account opens the rest:
- Every detail on this project
- News and media coverage
- Technical research
Free account · no card · lands you back on this project
